By Benjamin Chiou
Date: Thursday 17 Apr 2025
(Sharecast News) - Shares in Eli Lilly & Co were set to soar on Wednesday on the back of positive results of a late-stage trial of its weight-loss pill Orforglipron, which is thought to be a needle-free alternative to Novo Nordisk's popular injectable Ozempic drug.
Currency | US Dollars |
Share Price | $ 794.10 |
Change Today | $ -104.85 |
% Change | -11.66 % |
52 Week High | $960.02 |
52 Week Low | $720.91 |
Volume | 12,601,092 |
Shares Issued | 948.17m |
Market Cap | $752,942m |
Beta | 0.76 |
RiskGrade | 179 |
Strong Buy | 11 |
Buy | 10 |
Neutral | 5 |
Sell | 0 |
Strong Sell | 0 |
Total | 26 |
Time | Volume / Share Price |
15:59 | 200 @ $793.81 |
15:59 | 100 @ $794.09 |
15:59 | 100 @ $793.99 |
15:59 | 100 @ $793.92 |
15:59 | 100 @ $793.66 |
You are here: research